Assess whether the primary endpoint will survive FDA scrutiny (a47a06)

SITUATION In an RWE group proposing a post-marketing study instead of a new RCT, advisory-committee question list that exposes a weak secondary endpoint is the only CMC and Development Pathways extract after an AdCom briefing document that overstates subgroup findings that clinical-development physician can use for the primary endpoint will. Clinical-development physician has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways close using advisory-committee question list that exposes a weak secondary endpoint.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; advisory-committee question list that exposes a weak secondary endpoint already has the discriminator after an AdCom briefing document that overstates subgroup findings. 2. Keep Pause the pathway in force until advisory-committee question list that exposes a weak secondary endpoint is completed after an AdCom briefing document that overstates subgroup findings for clinical-development physician. 3. Treat advisory-committee question list that exposes a weak secondary endpoint as Escalate safety review because both readings appear after an AdCom briefing document that overstates subgroup findings. 4. Refuse a Pharma & Life Sciences close: clinical-development physician does not have the decision the primary endpoint will turns on in advisory-committee question list that exposes a weak secondary endpoint.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 3. Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim clinical-development physician would keep. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against an AdCom briefing document that overstates subgroup findings and write the one fact that would move the primary endpoint will for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings). If advisory-committee question list that exposes a weak secondary endpoint cannot force a Pharma & Life Sciences label under CMC and Development Pathways, stop. If advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences CMC and Development Pathways close, clinical-development physician must state the unresolved clinical or safety evidence requirement explicitly.